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Abstract
The development of a serological marker for early diag-
nosis  of  isocyanate-induced  occupational  asthma 
(isocyanate-OA) may improve clinical outcome. Our 
previous proteomic study found that expression of vi-
tamin D-binding protein (VDBP) was upregulated in the 
patients with isocyanate-OA. In the present study, we 
evaluated the clinical relevance of VDBP as a sero-
logical marker in screening for isocyanate-OA among 
exposed workers and its role in the pathogenesis of 
isocyanate-OA. Three study groups including 61 pa-
tients with isocyanate-OA (group I), 180 asymptomatic 
exposed  controls  (AECs,  group  II),  58  unexposed 
healthy controls (NCs, group III) were enrolled in this 
study.  The  baseline  serum  VDBP  level  was  sig-
nificantly higher in group I compared with groups II and 
III. The sensitivity and specificity for predicting the phe-
notype of isocyanate-OA with VDBP were 69% and 
81%, respectively. The group I subjects with high VDBP 
(≥ 311 μg/ml) had significantly lower PC20 methacho-
line levels than did subjects with low VDBP. The in vitro 
studies showed that TDI suppressed the uptake of 
VDBP into RLE-6TN cells, which was mediated by the 
downregulation of megalin, an endocytic receptor of 
the 25-hydroxycholecalciferol-VDBP complex. Further-
more, toluene diisocyanate (TDI) increased VEGF pro-
duction and secretion from this epithelial cells by sup-
pression of 1,25-dihydroxycholecalciferol [1,25(OH)2D3] 
production. The findings of this study suggest that the 
serum VDBP level may be used as a serological marker 
for the detection of isocyanate-OA among workers ex-
posed  to  isocyanate.  The  TDI-induced  VEGF  pro-
duction/secretion was reversed by 1,25(OH)2D3 treat-
ment, which may provide a potential therapeutic strat-
egy for patients with isocyanate-OA.
Keywords: asthma, occupational; biological mark-
ers; isocyanates; low density lipoprotein receptor-re-
lated protein-2; vascular endothelial growth factorA; 
vitamin D-binding protein320    Exp. Mol. Med. Vol. 44(5), 319-329, 2012
Group I
(n =6 1 )
Group II
(n = 180)
Group III
(n = 58)
   P-value
Age (years)* 
Sex (M/F) 
Working duration (years)
Atopy (%) 
Smoking history (%) 
Total IgE (IU/ml)* 
FEV1 (% pred)* 
43.48 ± 8.98
34/26
  6.70 ± 4.56
21 (34.4%)
12 (19.6%)
  281 ± 340
  85.12 ± 25.19
40.98 ± 8.58
116/64
10.75 ± 6.70
13 (7.2%)
45 (25%)
   232 ±  355
  100.93 ± 17.79
‡
28.80 ± 6.13
‡
21/37
NA
5 (8.6%)
1 (1.7%)
  82 ± 104
   97.90 ± 6.75
＜ 0.001
     0.002
     0.024
＜ 0.001
     0.321
     0.004
     0.002
Group I, isocyanate-induced occupational asthma; group II, asymptomatic exposed control; group III, unexposed healthy controls; NA, not available. 
*Values are expressed as means ± SD, 
†P ＜ 0.05, 
‡P ＜ 0.05 (group I vs. group II, or group III). Statistical significance of differences was determined by 
ANOVA with Bonferroni’s correction.
Table 1. Clinical characteristics of the subjects in the three study groups
Introduction
Three major isocyanates (toluene diisocyanate, 
TDI; hexamethylene diisocyanate, HDI; and diphe-
nylmethane diisocyanate, MDI) are highly reactive 
chemicals used in a variety of chemical manu-
facturing processes, such as production of polyur-
ethane forms and paints. Isocyanate-induced occu-
pational asthma (OA) is the most frequent cause of 
OA worldwide (Meredith and Nordman, 1996; 
Mannino, 2000), with a prevalence rate of around 
10% of exposed workers (Park and Nahm, 1997). 
Although the specific inhalation challenge test with 
isocyanate is the gold standard for the confirmative 
diagnosis of isocyanate-OA, this procedure re-
quires special equipment and is both time and la-
bor intensive. Furthermore, study of the long-term 
prognosis has shown that more than 50% of pa-
tients with isocyanate-OA have persistent asthma 
symptoms even after complete avoidance of ex-
posure and treatment with asthma medications 
(Park and Nahm, 1997). Therefore, early identi-
fication of patients may improve the long-term 
outcome. Previous studies focused on the de-
tection of serum-specific antibodies, which were 
not sufficiently specific to be used for diagnostic 
purposes (Cartier et al., 1989; Park et al., 2002; Ye 
et al., 2006; Wisnewski, 2007; Palikhe et al., 2011).
    More  recently,  proteomic  analysis,  a  process 
that includes purifying and identifying individual 
proteins from body fluids, has been used to devel-
op serological markers for diagnosis (Colantonio 
and Chan, 2005). The results of our previous study 
using proteomic analysis of patients with di-
phenyl-methane diisocyanate occupational asthma 
(MDI-OA) showed upregulation of vitamin D-bind-
ing protein (VDBP) expression (Hur et al., 2008a). 
There has been much interest in the role of the vi-
tamin D axis in lung disease such as asthma, 
chronic obstructive pulmonary disease and tuber-
culosis (Devereux et al., 2009; Janssens et al., 
2009; Wilkinson and Lange, 2009; Chishimba et 
al., 2010), which includes vitamin D and VDBP. 
Various cytokines, cellular elements, oxidative stress 
and protease/antiprotease levels affect lung fi-
broproliferation, remodeling and function, which 
may be influenced by vitamin D level (Gilbert et al., 
2009). Moreover, several previous studies have 
suggested the active involvement of VEGF in the 
pathogenesis of isocyanate-OA, which may be 
mediated by 1,25-dihydroxycholecalciferol [1,25(OH)2 
D3], the active form of vitamin D (Nakagawa et al., 
2005; Gruber et al., 2008). VEGF (Nakagawa et 
al., 2005; Gruber et al., 2008), a potent proangio-
genic cytokine, plays a central role in angio-
genesis, chronic airway inflammation, and airway 
remodeling in asthma (Voelkel et al., 2006; Walters 
et al., 2008).
    In the present study, the clinical relevance of the 
serum VDBP level was investigated as a potential 
candidate marker for screening susceptible subjects 
exposed to isocyanate. In addition, the mechanism 
associated with serum VDBP levels and isocyanate 
exposure was studied.
Results
Clinical characteristics of the study subjects
Sixty-one patients with isocyanate-OA (group I), 
confirmed by positive responses to isocyanate 
bronchial challenge test, and 180 asymptomatic 
exposed workers (AECs, group II) from same 
working environment, including spray-painting and 
polishing departments of the furniture and musical 
instrument industries or working in a car upholstery 
factory and a control group, 58 unexposed healthy 
controls (NCs, group III) were enrolled in this study. 
The clinical features of the three study groups are 
summarized in Table 1. Atopy was determined by a 
positive skin test to at least one common inhalant Vit D-binding protein in occupational asthma    321
Figure 1. Comparison of serum vitamin D-binding protein (VDBP) levels 
in the three study groups. group I, isocyanate induced occupational asth-
ma (isocyanate-IA); group II, asymptomatic exposed controls (AEC); 
group III, unexposed healthy controls (NC). The line indicates the mean 
value for each group. *P ＜ 0.001.
Clinical characteristic
Serum VDBP level (≥ 311 μg/ml )
P-value Higher group
 (≥ 311 μg/ml, n =7 7 )
Lower group 
(＜ 311 μg/ml, n =1 6 4 )
Age (yrs)
Sex (M/F)
Atopy status
Disease duration (yrs)
Exposed period to TDI (yrs)
FEV1 (% pred)
PC20 methacholine (mg/ml)
Total IgE (IU/ml)
43.26 ± 8.71
29/17
18/20
10.40 ± 6.73
  9.50 ± 5.61
  87.82 ± 22.46
  5.10 ± 8.19
  307 ± 350
40.84 ± 8.66
12/11
6/16
11.28 ± 7.70
  7.92 ± 6.21
  97.11 ± 22.07
  14.80 ± 11.25
  224 ± 346
0.051
0.442
0.174
0.509
0.395
0.083
0.001
0.225
Isocyanate-exposed subjects were divided into two groups according to the cutoff value of serum VDBP level: positive (≥ 11 μg/ml) and negative (＜311 
μg/ml) groups. Statistical significance was evaluated by Student’s t-test.
Table 2.  Comparison of the clinical characteristics between positive and negative groups among the isocyanate-exposed subjects
allergen, including house dust mites, Alternaria, cat 
fur, dog fur, a tree pollen mixture, a grass pollen 
mixture, and mugwort and ragweed pollens 
(Bencard, Bradford, UK). Serum samples from all 
study subjects were collected at initial examination; 
all subjects stopped using inhaled or oral steroids 
for 4 weeks before the study and underwent an 
interview, chest radiography, and skin prick test. In 
addition, five patients with isocyanate-OA and 
seven with AECs had additional blood sampling; 
the changes in the serum VDBP were observed 
before and after the isocyanate bronchial challenge 
tests. This study was reviewed and approved by 
the Institutional Review Board of Ajou Medical 
Center, Suwon, Korea, and all subjects gave 
written informed consent prior to enrollment in the 
study.
Comparison of serum VDBP levels in the three study 
groups
To validate the proteins identified by previous 
proteomic analysis, we compared baseline VDBP 
levels in the three study groups. Baseline serum 
levels of VDBP were compared among the three 
study groups, and the level was significantly higher 
in group I compared with groups II and III (497.30
± 432.71 μg/ml, 283.27 ± 114.47 μg/ml, 250.94 ±
42.72  μg/ml respectively, P ＜ 0.001); this 
remained significant after adjusting for age and 
gender (P ＜ 0.001), as shown in Figure 1.
Determination of the optimal cutoff levels for serum 
VDBP
To evaluate the diagnostic value of the serum 
VDBP level for discriminating between group I and 
II, a receiver operating characteristic (ROC) curve 
analysis was performed. An optimal cutoff value 
was selected from the ROC curve to obtain the 
highest sensitivity and specificity. When the cutoff 
for VDBP was selected as ≥311  μg/ml, the 
sensitivity and specificity were 69% and 81%, 
respectively, with 0.765 [95% confidence interval 
(CI), 0.688-0.843, P ＜ 0.001)] as the AUC, with a 
55% positive predictive value and an 88% negative 
predictive value.
        When the clinical parameters were compared 
according to the serum VDBP level in group I and 
II subjects, the subjects with a high serum VDBP 
level ≥ 311  μg/ml had significantly lower PC20 
methacholine levels (P =0.001). The baseline FEV1 
level (percent predicted value) tended to be lower 
in subjects with high serum VDBP levels, although 
statistical significance was not reached. No significant 
associations were noted between the serum VDBP 
level and other demographic and clinical parameters, 322    Exp. Mol. Med. Vol. 44(5), 319-329, 2012
Figure 2. Characteristics of FITC-VDBP uptake. RLE-6TN cells were in-
cubated in serum-free medium at 37
oC for 2 h with FITC-VDBP over a 
concentration range of 100-600 nM (A), and for a range of times from 30 
to 150 min with 400 nM FITC-VDBP (B). Serum-starved RLE-6TN cells 
were preincubated with a range of doses of 0.5-4 μM native VDBP for 30 
min and then incubated with 400 nM FITC-VDBP at 37
oC for 2 h (C). 
RLE-6TN cells were incubated in serum-free medium at 37
oC for 2 h with 
400 nM FITC-VDBP. The cells were then washed with PBS and treated 
with 1.2 mg/ml trypan blue. Then, FITC intensity was quantified by im-
munofluorescence assay as described in the Materials and Methods
section. Fluorescence intensities of the cells were counted using an im-
age browser, and data are presented as the percent intensity (D). All data 
are representative of three independent experiments. Values represent 
the means ± SEM.
such as age, gender, atopy status, total IgE level, 
and duration of working (Table 2).
Suppression of FITC-VDBP uptake into RLE-6TN 
cells by toluene diisocyanate (TDI)
To examine whether TDI exposure regulates VDBP 
uptake into RLE-6TN cells, in a rat alveolar epithelial 
cell line, the characteristics of FITC-VDBP uptake 
were determined using immunofluorescence analysis 
as described in the Materials and Methods section. 
The RLE-6TN cells were incubated in the absence 
or presence of FITC-VDBP at the indicated doses 
for 2 h. The results showed a dose-dependent in-
crease in fluorescence intensity, which approached 
saturation at about 400 nM (Figure 2A). The RLE-6TN 
cells were incubated with 400 nM FITC-VDBP for 
the indicated times, and the fluorescence intensity 
increased in a time-dependent manner, reaching 
saturation at 120 min (Figure 2B). Therefore, these 
conditions were used for further studies. To evaluate 
the effects of native VDBP on FITC-VDBP uptake 
into RLE-6TN cells, the cells were preincubated 
with 0.5, 2, or 4 μM native VDBP for 30 min and 
then incubated with 400 nM of FITC-VDBP for 2 h. 
The uptake of FITC-VDBP was suppressed up to 
88%, 51%, and 27%, respectively, compared with 
the untreated controls (Figure 2C). In addition, we 
performed a trypan blue quenching assay to de-
termine whether the measured fluorescence in-
tensity was due to a nonspecific membrane-bound 
protein. As shown in Figure 2D, when the RLE-6TN 
cells were treated with or without trypan blue, no 
significant changes were observed in the fluo-
rescence intensities, suggesting that this FITC-VDBP 
uptake assay was highly specific.
        When the RLE-6TN cells were incubated with 
0.5 and 1 mM TDI for 12 h, the FITC-VDBP uptake 
was decreased by 84.1% and 52.2%, respectively, 
compared with dimethyl sulfoxide (DMSO)-treated 
controls (Figure 3A). Similarly, when the RLE-6TN 
cells were incubated with 1 mM TDI for 3, 6, or 12 
h, its uptake was decreased by 84.9%, 74.3%, or 
47.6%, respectively, compared with the DMSO-treat-
ed controls (Figure 3B), indicating that TDI ex-
posure inhibited VDBP uptake into the RLE-6TN 
cells in a time- and dose-dependent manner. There 
was no cytotoxicity associated with TDI under the 
present experimental conditions (data not shown).
Downregulation of megalin mRNA and protein by TDI 
treatment in RLE-6TN cells
VDBP as a form of the 25-hydroxycholecalciferol 
[25(OH)D3]-VDBP complex is taken up into target 
cells by megalin (Nykjaer et al., 1999). To confirm 
the importance of megalin in VDBP uptake into the 
RLE-6TN cells, the RLE-6TN cells were preincubated 
with receptor-associated protein, a known inhibitor 
of megalin-mediated endocytosis. The uptake of 
FITC-VDBP was markedly blunted by up to 60% 
compared with the untreated controls (Figure 4A), 
suggesting that megalin mediated endocytic up-
take of FITC-VDBP into RLE-6TN cells. Real-time 
PCR analysis was performed to examine the regu-
latory effect of TDI on the level of megalin 
expression. When RLE-6TN cells were incubated 
with 0.5 and 1 mM TDI for 3 h, the level of megalin 
mRNA was decreased to 83.8% and 53.3% of the 
control, respectively (Figure 4B). When RLE-6TN 
cells were incubated with 1 mM TDI for 3, 6, or 9 h, 
megalin mRNA level was decreased to 53%, 
27.3%, or 26% of the control, respectively (Figure 
4C). In addition, Western blotting analysis indicated 
that megalin expression was downregulated by TDI Vit D-binding protein in occupational asthma    323
Figure 3. Time- and dose-dependent effects of toluene diisocyanate (TDI) on FITC-VDBP uptake in RLE-6TN cells. RLE-6TN cells were preincubated 
with 1 mM TDI for the indicated times and then incubated in serum-free medium with 400 nM FITC-VDBP at 37
oC for 2 h (A). RLE-6TN cells were pre-
incubated with the indicated doses of TDI for 6 h and then incubated in serum-free medium with 400 nM FITC-VDBP at 37
oC for 2 h. Fluorescence was 
examined using a fluorescence microscope. Scale bar, 20 μm. In the lower panel, fluorescent intensities of the cells were counted using an image brows-
er, and data are presented as percent intensity (B). All data are representative of three independent experiments. Values represent the means ± SEM. 
*P ＜ 0.05, **P ＜ 0.001 vs. control.
treatment (Figures 4D and 4E).
    To  evaluate  whether  TDI  inhibits  25(OH)D3 
uptake by downregulating megalin expression, 
RLE-6TN cells were incubated in the absence or 
presence of TDI (0.5-1 mM) for 6 h before incu-
bation with 1 μM 25(OH)D3 for 6 h. The level of 
1,25-dihydroxycholecalciferol [1,25(OH)2D3] production 
was decreased in a dose-dependent manner, as 
shown in Figure 5. These observations suggested 
that 1,25(OH)2D3 mediated its inhibitory action on 
VEGF secretion via an autocrine loop and that TDI 
inhibited the intracellular production of 1,25(OH)2D3 
by inhibiting 25(OH)D3 uptake by downregulating 
megalin expression.
Increased VEGF production and secretion through 
suppression of 1,25(OH)2D3 production
The production of 1,25(OH)2D3 has been associated 
with VEGF production and secretion (Nakagawa et al., 
2005; Gruber et al., 2008). To examine the possi-
bility that TDI regulates VEGF production and se-
cretion by regulating 1,25(OH)2D3 production in 
RLE-6TN cells, the effects of 1,25(OH)2D3 on 
VEGF production were investigated by Western 
blotting analysis. The cells were incubated with 
100 nM 1,25(OH)2D3 for 12, 24, or 48 h, and the 
resultant expression levels of VEGF were 100%, 
52%, and 45%, respectively, compared with the 
controls (Figure 6A). In addition, when RLE-6TN 
cells were incubated with 1, 10, or 100 nM 
1,25(OH)2D3 for 24 h, the resultant VEGF ex-
pression levels were 98%, 89%, and 58%, re-
spectively, compared with the controls (Figure 6B). 
These results suggest that 1,25(OH)2D3 inhibited 
VEGF production in the RLE-6TN cells. Next, when 
RLE-6TN cells were incubated with 1 mM TDI for 
3, 6, or 12 h, the expression level of VEGF was in-
creased by 40%, 66%, and 180%, respectively, 
compared with the control (Figure 6C). When the 
RLE-6TN cells were incubated with 0.5 and 1 mM 
TDI for 12 h, the level of VEGF expression was in-324    Exp. Mol. Med. Vol. 44(5), 319-329, 2012
Figure 4. Effects of TDI on megalin expression. RLE-6TN cells were pre-
incubated in serum-free medium with or without 1 μM receptor- asso-
ciated protein (RAP) for 30 min and then incubated with 400 nM 
FITC-VDBP at 37
oC for 2 h. The fluorescence was observed using a fluo-
rescence microscope. Scale bar, 20 μm. Fluorescence intensities of the 
cells were counted using an image browser, and data are presented as 
percent intensity (A). RLE-6TN cells were incubated with the indicated 
doses of TDI for 3 h, and then real-time PCR was performed (B). 
RLE-6TN cells were incubated with 1 mM TDI for the indicated times, 
and then real-time PCR was performed. The values are normalized rela-
tive to the GAPDH standard (C). RLE-6TN cells were incubated with the 
indicated doses of TDI for 12 h (D). RLE-6TN cells were incubated with 1 
mM TDI for the indicated times, and then Western blotting analysis for 
megalin was performed. Tubulin was used as a loading control (E). All 
data are representative of three independent experiments. Values repre-
sent the means ± SEM. *P ＜ 0.05, **P ＜ 0.001 vs. control.
Figure  5. Effects of toluene diisocyanate (TDI) on 1,25(OH)2D3
production. RLE-6TN cells were preincubated with the indicated doses of 
TDI for 6 h and then incubated with 1 μM 25(OH)D3 for 1, 3, or 6 h. 
1,25(OH)2D3 in the supernatant was quantified using an enzyme im-
munoassay kit. Data are representative of two independent experiments. 
Values represent the means ± SEM.
Figure  6. Effects of toluene diisocyanate (TDI) and 1,25(OH)2D3 on 
VEGF production and secretion. RLE-6TN cells were incubated with 100 
nM 1,25(OH)2D3 alone for the indicated times (A). RLE-6TN cells were in-
cubated with the indicated doses of 1,25(OH)2D3 alone for 24 h, and then 
Western blotting analysis for VEGF was performed. Tubulin was used as 
a loading control (B). RLE-6TN cells were incubated with 1 mM TDI for 
the indicated times (C). RLE-6TN cells were incubated with the indicated 
doses of TDI for 12 h, and then Western blotting analysis for VEGF was 
performed. Tubulin was used as a loading control (D). RLE-6TN cells 
were incubated with 1 mM TDI for 3, 6, or 12 h, and then the VEGF con-
centration in each supernatant was quantified using a rat ELISA kit (E). 
RLE-6TN cells were preincubated with the indicated doses of 
1,25(OH)2D3 for 24 h and then incubated with or without 1 mM TDI for 12 
h (F). All data are representative of three independent experiments. 
Values represent the means ± SEM. *P ＜ 0.001 vs. TDI(-) and 
1,25(OH)2D3(-); **P ＜ 0.001 vs. TDI(+).
creased by 54% and 210%, respectively, com-
pared with the control (Figure 6D). Similar effects 
of TDI on VEGF secretion were observed on 
ELISA (Figures 6E and 6F). Furthermore, when the 
cells were preincubated with 1,25(OH)2D3 for 24 h 
before treatment with 1 mM TDI for 12 h, VEGF se-
cretion was completely rescued by 100 nM 
1,25(OH)2D3 (Figure 6F). These findings sug-
gested that TDI exposure increased VEGF pro-
duction and secretion in RLE-6TN cells by sup-
pression of 1,25(OH)2D3 production.Vit D-binding protein in occupational asthma    325
Discussion
VDBP, also known as Gc globulin or group-specific 
component, is a multifunctional serum protein. 
VDBP has been reported to have a variety of im-
munological functions, such as in the actin cleav-
age system, macrophage activation, and chemo-
taxis of neutrophils, monocytes, and fibroblasts 
(White and Cooke, 2000; Meier et al., 2006). 
However, its major function is as a carrier of 
25(OH)D3, a major form of circulating vitamin D 
that is present in the form of the 25(OH)D3-VDBP 
complex. In our previous study, a proteomic ap-
proach with bronchoalveolar lavage fluid (BALF) 
was used as a screening tool to identify inflammatory 
mediators involved in the development of isocyanate- 
OA, where VDBP expression was upregulated in 
BALF of isocyanate-OA patients compared with 
AECs (Hur et al., 2008a). These findings were con-
sistent with those of previous studies where VDBP 
was identified in the BALF of asthma patients by 
proteomic analysis (Noel-Georis et al., 2002; Wu et 
al., 2005). In the present study, the serum VDBP 
level was found to be significantly higher in pa-
tients with isocyanate-OA compared with controls. 
Moreover, more severe airway hyperresponsiveness 
to methacholine was observed in subjects with ele-
vated serum VDBP levels than in those without 
elevated serum VDBP levels. In addition, the diag-
nostic value of the serum VDBP level showed sig-
nificantly increased sensitivity for identifying iso-
cyanate-OA; the sensitivity and specificity for dis-
crimination of isocyanate-OA in exposed workers 
were 69% and 81%, respectively. These values 
were comparable to those of previous studies in 
which serum-specific antibodies including serum-spe-
cific IgE and IgG antibodies to TDI-human serum 
albumin (HAS) conjugate, specific IgG to cytoker-
atin 19, and specific IgE and IgG antibodies to 
MDI-HSA (Cartier et al., 1989; Choi et al., 2004a; 
Ye et al., 2006; Wisnewski, 2007; Hur et al., 2008b) 
were evaluated as potential serological markers for 
TDI- or MDI-OA. When we measured serum VDBP 
level in the sera of 45 patients with allergic asthma 
recruited from Ajou University Hospital, it showed a 
similar VDBP level to that of group II, but showed a 
significantly lower level than that of group I (data 
not shown), indicating that increased serum level 
of VDBP may be a specific finding for iso-
cyanate-OA, not found in allergic asthma. In the 
previous study, we reported that the combined lev-
els of serum ferritin and transferrin may be useful 
as markers for differentiating subjects with MDI-OA 
among MDI-exposed workers with 71.43% sensi-
tivity and 85.71% specificity (Hur et al., 2008a). In 
this study, we found that measurement of serum 
VDBP level is a simple and reproducible method 
that can be used in larger cohorts of exposed 
workers with a commercial ELISA kit; it is less ex-
pensive to measure one protein than two proteins, 
i.e., ferritin and transferrin. Based on these find-
ings, the serum VDBP level may be a useful sero-
logical marker for differentiating subjects with iso-
cyanate-OA from AEC and for predicting the se-
verity of airway hyperresponsiveness among pa-
tients with isocyanate- OA.
    This is the first study to suggest the potential in-
volvement of VDBP in the pathogenesis of iso-
cyanate-OA. First, we focused on the function of 
VDBP as a major carrier protein of vitamin D, 
which is known to be associated with immune 
modulation of T helper 2 inflammation and an in-
dividual’s susceptibility to asthma (Cantorna et al., 
2004; Hughes and Norton, 2009). Previous studies 
demonstrated that the 25(OH)D3-VDBP complex 
moved compounds to target tissues that were tak-
en up into cells; this process was mediated by an 
endocytic mechanism via megalin (Nykjaer et al., 
1999, 2001; Rowling et al., 2006). Mice lacking 
megalin were found to develop vitamin D defi-
ciency or rickets due to loss of VDBP and vitamin 
D metabolites (Dusso et al., 2005), indicating that 
megalin is a major endocytic receptor for the up-
take of vitamin D. Once taken up into the target 
cells, 25(OH)D3 was dissociated from VDBP and 
metabolized to 1,25(OH)2D3. Megalin is expressed 
not only in the kidney cells (Nykjaer et al., 1999; 
Hosojima et al., 2009) but also in the alveolar epi-
thelial cells (Lundgren et al., 1997). The results of 
the present study showed that TDI exposure sup-
presses VDBP and 25(OH)D3 uptake along with 
downregulating megalin expression in a dose- and 
time-dependent manner in RLE-6TN cells. These 
results suggest that TDI exposure may lead to 
higher VDBP levels in exposed tissue, such as 
BALF, in susceptible workers by suppressing meg-
alin expression in lung alveolar cells.
    It is postulated that VEGF could act as an angio-
genic factor that is capable of altering subepithelial 
vascularity, which would increase pulmonary micro-
vascular permeability, thus enhancing airway in-
flammation and remodeling in patients with TDI- 
and MDI-OA (Weyel and Schaffer, 1985; Mapp et 
al., 1988; Nabe et al., 2005). In addition, the VEGF 
level increased in the BALF after TDI challenge in 
a murine model of TDI-OA (Lee et al., 2002) and in 
the induced sputum of TDI-induced asthma 
patients. (Choi et al., 2004b) VEGF appears to play 
an important role, at least in part, in the patho-
genesis of isocyanate-OA (Weyel and Schaffer, 
1985; Mapp et al., 1988; Nabe et al., 2005). 
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a negative regulatory effect on VEGF production 
and secretion (Nakagawa et al., 2005; Gruber et 
al., 2008). The mechanism by which 1,25(OH)2D3 
regulates VEGF expression and secretion is cur-
rently unclear. However, a few mechanisms have 
been suggested. First, it may be related to the rap-
id induction of non-transcriptional responses, which 
may occur via activation of transmembrane sig-
nal-transduction pathways, such as protein kinase 
C, phosphatidylinositol 3-kinase/Akt, and p42/p44 
MAP kinase (Nemere et al., 1998; Ma et al., 2006; 
Gruber et al., 2008), where all of the kinases were 
closely associated with VEGF expression (Berra et 
al., 2000; Aida et al., 2005). 1,25(OH)2D3 induced 
rapid and sustained activation of phosphatidylinosi-
tol 3-kinase/Akt, this effect was nongenomic (Ma et 
al., 2006). Swain et al. reported 1,25(OH)2D3 may 
regulate phopholipase C production by the cells, 
which, in turn, may modulate signal transduction by 
receptors with tyrosine kinase activity, including 
VEGF. (Swain et al., 1992). Second, 1,25(OH)2D3 
may modulate the expression of growth factor re-
ceptors (Koga et al., 1988). Finally, growth factors 
could modulate the expression of the nuclear vita-
min D receptor (Haussler et al., 1998). The central 
role of vitamin D receptor in the biology of vitamin 
D action has been known at the molecular level. In 
the present study, TDI exposure increased VEGF 
production and secretion from RLE-6TN cells by 
suppression of 1,25(OH)2D3 production, which was 
reversed by 1,25(OH)2D3 treatment. This is the first 
study to demonstrate the regulatory effects of 
1,25(OH)2D3 on TDI-induced VEGF production and 
secretion. The administration of 1,25(OH)2D3 may 
reduce VEGF-induced airway inflammation in pa-
tients with isocyanate-OA. Although further studies 
are needed to elucidate the mechanisms by which 
TDI decreases megalin expression and 1,25(OH)2D3 
decreases VEGF production and secretion, this in-
formation may provide insight to facilitate the de-
velopment of new therapeutic strategies for the 
treatment of isocyanate-OA.
    In conclusion, the results of this study demonstrated 
that the measurement of serum VDBP levels may 
be a useful serological marker for the early detection 
of isocyanate-OA among exposed workers. TDI- 
induced VEGF production/secretion may be re-
versed by 1,25(OH)2D3 treatment, which may pro-
vide a potential therapeutic strategy for isocyanate- 
OA.
Methods
Bronchial challenge testing with methacholine and 
isocyanate
All subjects with asthma underwent lung function measure-
ment and inhalation challenge tests with methacholine and 
isocyanate. Airway responsiveness to methacholine was 
tested using the five-breath dosimeter protocol, as de-
scribed previously (Park et al., 1999; Ye et al., 2006). The 
methacholine PC20 level was determined by interpolation 
from the dose-response curve. The isocyanate (TDI or 
MDI) bronchial challenge tests were performed according 
to the method described previously (Park et al., 1999; Ye et 
al., 2006).
Measurement of VDBP levels in the sera
The level of VDBP in sera was measured using a commer-
cially available ELISA kit (Immunodiagnostik AG, Bensheim, 
Germany) according to the manufacturer’s instructions. 
The serum samples were diluted 1:10000 just before the 
assay to ensure that the measured values were within the 
optimal range of the standard curve. The inter- and in-
tra-assay variations of this ELISA kit were under 19.3% 
and 5.0%, respectively.
Cell culture and treatment with TDI
The rat alveolar epithelial cell line RLE-6TN, which was 
characterized and found to be similar to alveolar type 2 
cells, including the expression of cytokeratin 19 (Paine et 
al., 1988; Driscoll et al., 1995), was purchased from the 
American Type Culture Collection (Manassas, VA). The 
cells were cultured in D-MEM/F-12 containing 10% FBS, 
100 IU/ml penicillin, and 100 μg/ml streptomycin, in an at-
mosphere of 5% CO2 and 95% air at 37
oC. TDI (Sigma, St. 
Louis, MO) was thawed at 37
oC, then diluted in DMSO 
(1:20, v/v). When the cells were treated with TDI, controls 
were treated with an equivalent amount of DMSO; the final 
DMSO concentration was less than 0.3% (v/v).
Real-time reverse transcriptase-PCR
Total RNA was isolated from RLE-6TN cells using an 
Easy-BLUE Total RNA Extraction Kit (iNtRON Biotechnologies, 
Seoul, Korea) after exposure to 0.5-1 mM TDI for 3-12 h. 
Total RNA (2 μg) was reverse transcribed using the oligo 
(dT) primer and MMLV reverse transcriptase (Promega, 
Madison, WI) at 42
oC for 90 min. Real-time PCR was per-
formed using an ABI Prism 7500 instrument according to 
the manufacturer’s instructions (Applied Biosystems, 
Foster City, CA). The following primer pairs were used: 
megalin, forward 5′-TGGAATCTCCCTTGATCCTG-3′ and 
reverse, 5′-TGTTGCTGCCATCAGTCTTC-3′; and GAPDH, 
forward 5′- GGCCAAAAGGGTCATCATC-3′ and reverse, 
5′-GTGATGGCATGGACTGTGG-3′. After an initial hot start 
for 10 min, amplification was performed for 40 cycles con-
sisting of denaturation for 10 s at 94
oC, annealing for 30 s 
at 56
oC, and extension for 40 s at 72
oC. The amplification 
kinetics was recorded as sigmoid progress curves for 
which fluorescence was plotted against the number of am-
plification cycles. The threshold cycle number (CT) was 
used to define the initial amount of each template. The CT 
was the first cycle for which a detectable fluorescent signal 
was observed. The mRNA expression levels were de-
termined and compared with the GAPDH standard.Vit D-binding protein in occupational asthma    327
Preparation of FITC-VDBP conjugate and 
immunofluorescence staining
VDBP was purchased from Calbiochem (La Jolla, CA). 
FITC-VDBP conjugate was prepared using a Pierce FITC 
antibody labeling kit according to the manufacturer’s in-
structions (Pierce, Rockford, IL). For the in vitro VDBP-up-
take studies, aliquots of 2 × 10
4 of the RLE-6TN cells 
were seeded on cover slips in 24-well plates. The next day, 
the cells were preincubated with or without 0.5-1 mM TDI 
for 3-12 h, washed twice with PBS, and incubated with 400 
nM FITC-VDBP conjugate in serum-free medium for 2 h. 
For competition assay, the cells were incubated in the ab-
sence or presence of the indicated doses of native VDBP 
for 30 min and then incubated with 400 nM FITC-VDBP for 
2 h. For the trypan blue quenching assay, the cells were in-
cubated with FITC-VDBP conjugate and then incubated 
with or without 1.2 mg/ml trypan blue (Sigma, St. Louis, 
MO) for 15 min to quench the extracellular fluorescence 
signal. After washing, the cells were fixed with 4% paraf-
ormaldehyde and observed under a fluorescence micro-
scope (Carl Zeiss, Jena, Germany). More than 30 cells per 
field were randomly selected from each of five fields in 
three separate experiments, and the fluorescence intensity 
was determined by processing FITC images at the cellular 
level; the percent intensity was calculated as the mean flu-
orescence intensity of the sample divided by that of the 
control.
Western blotting analysis
Cell lysates were separated by 5% (for megalin) or 10% 
SDS-PAGE. The membranes were blocked in blocking sol-
ution (5% nonfat dried milk in PBS) for 1 h at room temper-
ature and then probed with anti-megalin, anti-VEGF (Santa 
Cruz Technology, Santa Cruz, CA), and anti-tubulin (Sigma) 
antibodies for 1 h at room temperature. After washing three 
times with PBS containing 0.1% Tween-20 (PBS-T), the 
membranes were incubated with secondary antibodies 
(Cell Signaling Technology, Beverly, MA) for 1 h at room 
temperature. After washing an additional three times in 
PBS-T, the membranes were developed using an ECL sol-
ution (Pierce, Rockford, IL) and exposed to Chemidoc XRS 
Gel Documentation System (Bio-Rad, Hercules, CA).
Measurement of 1,25(OH)2D3 production and VEGF 
secretion
RLE-6TN cells were incubated with 1 mM TDI for 6 h and 
then further incubated with 1 μM 25(OH)2D3 (Sigma) for 1, 
3, or 6 h. 1,25(OH)2D3 in the supernatant was quantified 
using an enzyme immunoassay kit for 1,25(OH)2D3 
(Immunodiagnostic Systems, Boldon, UK) according to the 
manufacturer’s instructions. For detecting VEGF, the RLE-6TN 
cells were incubated with 1 mM TDI for 3, 6, or 12 h or in-
cubated with 1, 10, or 100 nM 1,25(OH)2D3 for 24 h before 
treatment with 1 mM TDI for 12 h. The VEGF level in the 
supernatant was quantified using an ELISA kit for rat 
VEGF (Invitrogen, Camarillo, CA) according to the manu-
facturer’s instructions.
Statistical Analyses
All values are expressed as the means ± SEM, unless 
otherwise stated. The significance of differences among 
groups was evaluated by the Student’s t-test and χ
2 test. 
Comparison of the serum VDBP in each group was per-
formed by ANOVA with Bonferroni’s correction. Wilcoxon’s 
test was used to compare VDBP levels in sera obtained 
before and after isocyanate bronchial challenge tests with-
in the groups. A ROC curve was constructed to evaluate 
the diagnostic value of the serum VDBP for discrimination 
between isocyanate-OA and AECs, and the AUC with 95% 
CI was computed. Sensitivity and specificity were calcu-
lated according to the identified optimal cutoffs. All analy-
ses were carried out using SPSS 13.0 software (SPSS 
Inc., Chicago, IL). In all analyses, P ＜ 0.05 was taken to 
indicate statistical significance.
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